Your browser doesn't support javascript.
loading
Impact of Preexisting Hepatitis C Virus Genotype 6 NS3, NS5A, and NS5B Polymorphisms on the In Vitro Potency of Direct-Acting Antiviral Agents.
McPhee, Fiona; Ueland, Joseph; Vellucci, Vincent; Bowden, Scott; Sievert, William; Zhou, Nannan.
Affiliation
  • McPhee F; Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA fiona.mcphee@bms.com.
  • Ueland J; Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA.
  • Vellucci V; Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA.
  • Bowden S; Victorian Infectious Diseases Reference Laboratory, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.
  • Sievert W; Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia.
  • Zhou N; Bristol-Myers Squibb Research and Development, Wallingford, Connecticut, USA.
Antimicrob Agents Chemother ; 63(4)2019 04.
Article in En | MEDLINE | ID: mdl-30718256
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Polymorphism, Genetic / Hepatitis C / Viral Nonstructural Proteins / Hepacivirus Limits: Humans Language: En Journal: Antimicrob Agents Chemother Year: 2019 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antiviral Agents / Polymorphism, Genetic / Hepatitis C / Viral Nonstructural Proteins / Hepacivirus Limits: Humans Language: En Journal: Antimicrob Agents Chemother Year: 2019 Type: Article Affiliation country: United States